Investment Thesis
MeiraGTx is a pre-revenue biotech company in financial distress with negative stockholders equity of -$58.1M, indicating balance sheet insolvency. While positive cash flows ($15.8M FCF) extend runway, massive operating losses (-$40.8M) on negligible revenue ($293K) with a current ratio of 0.55x suggest imminent refinancing pressure. Early-stage biotech carries binary outcomes, but fundamentals indicate significant default risk.
Strengths
- Positive free cash flow of $15.8M and operating cash flow of $17.8M despite net losses
- Cash position of $71.5M provides approximately 1.5 years runway at current burn rates
- Revenue growth of +144.6% YoY demonstrates traction from initial commercialization
Risks
- Negative stockholders equity of -$58.1M indicates balance sheet insolvency and liabilities exceed assets by $58.1M
- Operating losses of $40.8M against minimal revenue of $293K with unclear path to profitability
- Current ratio of 0.55x and quick ratio of 0.54x signal liquidity stress; refinancing may be required within 18-24 months
Key Metrics to Watch
- Stockholders equity trajectory and balance sheet stabilization
- Cash burn rate and monthly cash consumption vs. available reserves
- Clinical trial progress and regulatory milestones affecting revenue realization timeline
Financial Metrics
Revenue
293.0K
Net Income
-46.3M
EPS (Diluted)
$-0.57
Free Cash Flow
15.8M
Total Assets
244.7M
Cash
71.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-13,930.7%
Net Margin
-15,806.5%
ROE
N/A
ROA
-18.9%
FCF Margin
5,393.2%
Balance Sheet & Liquidity
Current Ratio
0.55x
Quick Ratio
0.54x
Debt/Equity
N/A
Debt/Assets
123.8%
Interest Coverage
-14.33x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:14:00.895368 |
Data as of: 2026-03-31 |
Powered by Claude AI